← Back to patent-cliff list
Avenciguat
Tier C — Watch / tradeAvenciguat
Boehringer Ingelheim
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：sGC
Indications (approved)：Systemic sclerosis, Diabetic nephropathy, Chronic renal impairment, Kidney disease, Liver disease, Portal hypertension, Liver cirrhosis, 腹水
Regional status
US
Phase II
2021-04-27
EU
Phase II
2021-04-27
China
Phase II
2021-04-27
Japan
Phase II
2021-04-27
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Avenciguat?
Approved indications include: Systemic sclerosis, Diabetic nephropathy, Chronic renal impairment, Kidney disease, Liver disease, Portal hypertension, Liver cirrhosis, 腹水.
When does the Avenciguat patent expire?
No public expiry year is available for Avenciguat yet; this page updates once verified.
How do I get a quote for Avenciguat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06